Effect of Low Positive End of Treatment Viral Load with Direct-Acting Antiviral Therapy on Sustained Virologic Response

Table 1

Demographic, baseline lab, and treatment characteristics in EOT positive viral load patients.

Patient	Gender	Race	Age	BMI (kg/m^2)	INR	Albumin (g/dL)	Total bilirubin (mg/dL)	Platelet (x 1,000/mm^3)	ALT (IU/L)	Baseline viral load (IU/mL)	Week 4 viral load (IU/mL)	EOT viral load (IU/mL)	Genotype	Fibrosis level (stage)	Treatment regimen	Previous treatment	SVR 12/24
1	F	Caucasian	70	30	—	3.6	1	312	53	3,715,090	Neg	62	1a	2	SOF + SIM	Peg-IFN + RBV	Y/Y
2	F	Caucasian	62	27	1.1	4.4	0.6	218	77	3,895,292	<15	235	2b	—	SOF + RBV	—	Y/Y
3	F	Caucasian	64	32	—	3.9	0.31	189	27	3,200,000	Neg	26	1b	0	SOF + LED	—	Y/Y
4	F	Black	71	27	—	3.6	0.4	357	35	971,341	Neg	<15	1a	—	SOF + LED	—	Y/Y
5	M	Caucasian	53	23	—	4	0.5	183	39	2,108,530	Neg	Neg	1a	—	SOF + LED	Peg-IFN + RBV	Y/Y
6	M	Caucasian	29	29	—	0.3	0.3	340	118	1,540,000	120	28	1a	0	SOF + LED	—	Y/Y
7	M	Caucasian	68	30	1.2	1.1	1.1	86	73	3,001,000	640	62	1a	4	SOF + LED	—	Y/Y
8	F	Caucasian	52	—	1.1	1.1	1.1	94	82	2,300,000	206	18	1a	4	SOF + VEL + VOX	Peg-IFN + RBV SOF + LED	Y/Y
9	F	Caucasian	62	—	0.9	0.4	0.4	239	157	2,108,530	128	14	1a	2	GLE + PIB	—	Y/Y

Patients had a negative EOT viral load, but 23 IU/mL at week four after EOT. Abbreviations: SOF, sofosbuvir; SIM, simeprevir; peg-IFN, pegylated interferon; RBV, ribavirin; LED, ledipasvir; VEL, velpatasvir; VOX, voxilaprevir; GLE, glecaprevir; PIB, pibrentasavir.